久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

日本 ,安斯泰來,Astellas,   
安斯泰來制藥集團(tuán)是一家總部位于日本東京的研發(fā)型制藥企業(yè)，在全球范圍內(nèi)研發(fā)、生產(chǎn)、銷售創(chuàng)新型醫(yī)藥產(chǎn)品。我們的使命是不斷提升企業(yè)價(jià)值，致力于通過創(chuàng)新可靠的醫(yī)藥產(chǎn)品為全世界人民的健康做貢獻(xiàn)實(shí)現(xiàn)我們的存在意義。

　　安斯泰來已經(jīng)在需要高度專業(yè)技能的器官移植領(lǐng)域和泌尿領(lǐng)域成為全球?qū)I(yè)治療領(lǐng)域領(lǐng)導(dǎo)者。借助獨(dú)特的產(chǎn)品線，我們逐步在其他目標(biāo)領(lǐng)域培養(yǎng)支柱產(chǎn)品。在抗腫瘤領(lǐng)域，我們擁有了先進(jìn)的抗體藥物研究技術(shù)。同時(shí)強(qiáng)大的現(xiàn)金流確保我們能夠持續(xù)投資于未來的成長。

　　在2007財(cái)務(wù)年度 (2007 年 4 月至 2008 年 3 月) 全球凈銷售額達(dá) 9,726 億日元（97 億美元）。安斯泰來已經(jīng)成為日本第二大處方藥品公司，全世界排名 20位的制藥企業(yè)。目前全球員工約 14000 人。


為方便廣大患者、醫(yī)師及合作伙伴與安斯泰來制藥（中國）有限公司的積極聯(lián)絡(luò)與溝通，及時(shí)處理來自各方的咨詢反饋， 安斯泰來中國于即日正式啟用400客戶咨詢專線：4000-8567-99，歡迎使用！

專線服務(wù)對象：患者、醫(yī)院、藥房、藥品經(jīng)營公司等。
服務(wù)范圍：處理與安斯泰來中國上市產(chǎn)品有關(guān)的用藥咨詢、藥品不良反應(yīng)報(bào)告、藥品真?zhèn)伪鎰e咨詢、購藥咨詢、質(zhì)量投訴等。
工作時(shí)間：9:00-17:30（周一至周五），非工作時(shí)間可根據(jù)語音提示留言，我們會盡快與您聯(lián)絡(luò)！

 Astellas Pharma Inc. (アステラス製薬株式會社, Asuterasu Seiyaku Kabushiki-gaisha?, TYO: 4503) is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之內(nèi)製薬株式會社, Yamanouchi Seiyaku Kabushiki-gaisha?) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業(yè)株式會社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha?).

Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

The company's headquarters are in Tokyo, with research centres in Tsukuba and Osaka. Clinical development is centred in Deerfield, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people.

Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943.

Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942.

Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards. Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D centre in Deerfield, Illinois. Yamanouchi's R&D centre in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991.

Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April 2005.

[edit] Products
Some of the key products produced by Astellas include:

Prograf (tacrolimus) - Prevention of post-transplant organ rejection
Protopic (tacrolimus ointment) - Atopic dermatitis (eczema)
Amevive (alefacept) - Plaque psoriasis
VESIcare (solifenacin succinate) - Overactive bladder (OAB)
Flomax (tamsulosin hydrochloride) - Benign prostatic hyperplasia (BPH)
Adenocard (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
Adenoscan (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
Lexiscan (regadenoson injection) - Pharmacologic stress agent for myocardial perfusion scan
Vaprisol (conivaptan) - Hyponatremia
AmBisome (amphotericin B) - Anti-fungal
Mycamine (micafungin sodium) - Anti-fungal
Vibativ (telavancin) - Antibiotic